POST Online Media Lite Edition


Nile Therapeutics promotes Darlene Horton to CEO and director

Staff writer |
San Mateo, Ca., USA - August 7, 2012, San Mateo, Ca., USA - Nile Therapeutics, Inc., a biopharmaceutical company, announced that it has promoted Darlene Horton to president and chief executive officer, and appointed her as a director of the company.

Article continues below

Dr. Horton served as Nile's Chief Medical Officer from June 2012 until her appointment as its CEO. Previously, she served as Chief Medical Officer of Itero Biopharmaceuticals, a venture-backed biosimilar company. Previous to Itero, Dr. Horton served as Senior Vice President, Clinical Research at Scios, Inc., a Johnson & Johnson (J&J) company.

During her 12 year tenure at Scios, she was the clinical lead for Natrecor, a commercial product indicated for the treatment of acute heart failure. Dr. Horton led the Natrecor program from late-stage development through FDA approval and commercialization, and was also part of the senior management team at the time of Scios's acquisition by J&J. Dr. Horton also served as the Head of the Cardiovascular Therapeutic Area Center of Excellence for J&J pharmaceutical companies.


What to read next

Qualcomm Elects Thomas Horton to Board of Directors
Thomas W. Horton new president of AMR and American Airlines
A. Schulman appoints Andrean R. Horton as EVP